Andrx Corporation, along with its subsidiaries, researches, develops, manufactures, commercializes, and distributes generic versions of controlled-release pharmaceuticals, oral contraceptives, and generic versions of immediate-release products. The company also develops and commercializes brand name pharmaceuticals; and distributes primarily generics that are commercialized by others and its own products. In addition, it offers contract services, such as development and manufacture of pharmaceutical products, including combination products and controlled-release formulations for other pharmaceutical companies; and contract research and development services. It sells generic products through ...
4955 Orange Drive
Davie, FL 33314
Founded in 1992
Horizon Pharma, Inc. Files Suit in United States District Court for the District of New Jersey Against Watson Laboratories, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc
Aug 28 13
On August 26, 2013, Horizon Pharma, Inc. filed suit in the United States District Court for the District of New Jersey against Watson Laboratories, Inc. - Florida, Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. (collectively, WLF). The lawsuit alleges that WLF has infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124, and 8,394,407 by filing an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic versions of RAYOS containing 1 mg, 2 mg, and 5 mg of prednisone prior to the expiration of the patents. The subject patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Commencement of the patent infringement lawsuit stays, or bars, FDA approval of WLF's ANDA for 30 months or until an earlier district court decision that the subject patents are not infringed or invalid.
Mylan Pharmaceuticals Inc. Announces Settlement Agreement with Shionogi Inc. and Andrx to Resolve Patent Litigation
Mar 13 13
Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This product is the generic version of Shionogi's Fortamet(R), and is indicated as an adjunct to diet and exercise to lower blood glucose. Under the terms of the settlement agreement, Mylan may launch a generic version of Fortamet(R) on August 1, 2013, or earlier under certain conditions. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.